ZOMETA® Reduces Skeletal-Related Events From Bone Metastases In Multiple Myeloma Patients
Home

Videos
View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

 
European Summary of Product Characteristics
For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics 		 
About ZOMETA®: Multiple Myeloma About ZOMETA: defend against SREs across a broad range of tumor types

Threat of SREs What are SREs ZOMETA® reduces SREs Dose ZOMETA® every 3 to 4 weeks References


ZOMETA®effectively helps to protect patients with multiple myeloma from the threat of SREs

Time to first SRE, ZOMETA vs placebo in patients with multiple myeloma6

  • ZOMETA delivered equivalent efficacy to that of pamidronate in delaying SREs (376 days vs 356 days, respectively) for patients with multiple myeloma or breast cancer in a noninferiority trial6

ZOMETA can delay and reduce SREs in patients with multiple myeloma and bone lesions6
 

Disclaimer: This is an international website for ZOMETA® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US flag at the top right corner of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

About ZOMETA | ZOMETA Patient Case Studies | ZOMETA Dosing & Administration | ZOMETA Safety & Tolerability | ZOMETA Clinical News | ZOMETA For Your Patients | Professional Resource Center
ZOMETA Around the World

About Novartis OncologySiteMapContactPrivacy
 


Use of this website is subject to our Terms of Use
© 2010 Novartis AG.